Literature DB >> 19787152

Neonatal screening for cystic fibrosis in São Paulo State, Brazil: a pilot study.

R Rodrigues1, P K R Magalhaes, M I M Fernandes, C S Gabetta, A F Ribeiro, K P Pedro, F Valdetaro, J L F Santos, R M de Souza, A Pazin Filho, L M Z Maciel.   

Abstract

Cystic fibrosis is one of the most common autosomal recessive hereditary diseases in the Caucasian population, with an incidence of 1:2000 to 1:3500 liveborns. More than 1000 mutations have been described with the most common being F508del. It has a prevalence of 23-55% within the Brazilian population. The lack of population-based studies evaluating the incidence of cystic fibrosis in São Paulo State, Brazil, and an analysis concerning the costs of implantation of a screening program motivated the present study. A total of 60,000 dried blood samples from Guthrie cards obtained from April 2005 to January 2006 for neonatal screening at 4 reference centers in São Paulo State were analyzed. The immunoreactive trypsinogen (IRT)/IRT protocol was used with the cut-off value being 70 ng/mL. A total of 532 children (0.9%) showed IRT >70 ng/mL and a 2nd sample was collected from 418 (80.3%) of these patients. Four affected children were detected at two centers, corresponding to an incidence of 1:8403. The average age at diagnosis was 69 days, and 3 of the children already showed severe symptoms of the disease. The rate of false-positive results was 95.2% and the positive predictive value for the test was 8%. The cost of detecting an affected subject was approximately US$8,000.00 when this cystic fibrosis program was added to an existing neonatal screening program. The present study clearly shows the difficulties involved in cystic fibrosis screening using the IRT/IRT protocol, particularly in a population with no long-term tradition of neonatal screening.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19787152     DOI: 10.1590/s0100-879x2009005000017

Source DB:  PubMed          Journal:  Braz J Med Biol Res        ISSN: 0100-879X            Impact factor:   2.590


  4 in total

1.  Newborn Screening for Cystic Fibrosis in Mersin Province: Yearly Assessment of the National Program.

Authors:  Ali Özdemir; Dilek Doğruel
Journal:  Turk Thorac J       Date:  2020-03-01

2.  Measurements of Functional Responses in Human Primary Lung Cells as a Basis for Personalized Therapy for Cystic Fibrosis.

Authors:  Nikhil T Awatade; Inna Uliyakina; Carlos M Farinha; Luka A Clarke; Karina Mendes; Amparo Solé; Juan Pastor; Maria Margarida Ramos; Margarida D Amaral
Journal:  EBioMedicine       Date:  2014-12-17       Impact factor: 8.143

3.  Profile of cystic fibrosis in a single referral center in Egypt.

Authors:  Mona M El-Falaki; Walaa A Shahin; Noussa R El-Basha; Aliaa A Ali; Dina A Mehaney; Mona M El-Attar
Journal:  J Adv Res       Date:  2013-07-15       Impact factor: 10.479

Review 4.  The Role of Extended CFTR Gene Sequencing in Newborn Screening for Cystic Fibrosis.

Authors:  Anne Bergougnoux; Maureen Lopez; Emmanuelle Girodon
Journal:  Int J Neonatal Screen       Date:  2020-03-21
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.